FRANKFURT, April 30 (Reuters) - Bayer brushed off concern that its stroke prevention pill Xarelto may be losing market share to rival Bristol-Myers Squibb's Eliquis in the United States.
The German drugmaker told analysts during a conference call on Thursday that Eliquis was taking business from warfarin and other drugs, but not from Xarelto.
06:13 Pound quivers near three-month low, stocks weak before May's Brexit stance speech12
12:23 Sterling volatile as market speculates on ‘hard Brexit’; investors await May's speech14
01:03 Sterling slides to three-month lows on 'hard Brexit' fears11
22:15 Sterling skids on Brexit anxiety; investors hope for Donald Trump clarity13